The SARS-CoV-2 outbreak has disrupted the delivery of routine healthcare services on a global scale. With many regions suspending the provision of non-essential healthcare services, there is a risk that patients with common treatable illnesses do not receive prompt treatment, leading to more serious and complex presentations at a later date. Lemierre’s syndrome is a potentially life-threatening and under-recognised sequela of an oropharyngeal or dental infection. It is characterised by septic embolisation of the gram-negative bacillus Fusobacterium necrophorum to a variety of different organs, most commonly to the lungs. Thrombophlebitis of the internal jugular vein is frequently identified. We describe an atypical case of Lemierre’s syndrome involving the brain, liver and lungs following a dental infection in a young male who delayed seeking dental or medical attention due to a lack of routine services and concerns about the SARS-CoV-2 outbreak.

Background: The current coronavirus disease 2019 (COVID-19) pandemic began in Ireland with the first confirmed positive case in March 2020. In the early stages of the pandemic clinicians and researchers in two affiliated Dublin hospitals identified the need for a COVID-19 biobanking initiative to support and enhance research into the disease. Through large scale analysis of clinical, regional, and genetic characteristics of COVID-19 patients, biobanks have helped identify, and so protect, at risk patient groups The STTAR Bioresource has been created to collect and store data and linked biological samples from patients with SARS-CoV-2 infection and healthy and disease controls. Aim: The primary objective of this study is to build a biobank, to understand the clinical characteristics and natural history of COVID-19 infection with the long-term goal of research into improved disease understanding, diagnostic tests and treatments. Methods: This is a prospective dual-site cohort study across two tertiary acute university teaching hospitals. Patients are recruited from inpatient wards or outpatient clinics. Patients with confirmed COVID-19 infection as well as healthy and specific disease control groups are recruited. Biological samples are collected and a case report form detailing demographic and medical background is entered into the bespoke secure online Dendrite database. Impact: The results of this study will be used to inform national and international strategy on health service provision and disease management related to COVID-19. In common with other biobanks, study end points evolve over time as new research questions emerge. They currently include patient survival, occurrence of severe complications of the disease or its therapy, occurrence of persistent symptoms following recovery from the acute illness and vaccine responses.

We describe a case of brucellosis in a man in his 20s, who presented to the emergency department with a 1-month history of fevers, dry cough and knee pain. Blood cultures were positive after 55 hours and Ochrobactrum daejeonense was identified on matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass spectrometry. Ochrobactrum spp are Gram-negative organisms that are phylogenetically related to Brucella spp but commercially available MALDI-TOF libraries cannot distinguish between the two genera. Further positive blood cultures for O. daejeonense combined with characteristic growth patterns for Brucella spp led to targeted questioning of the patient regarding potential exposure risks, which revealed a history of consumption of unpasteurised camel milk in the Middle East 3 months earlier. Treatment of brucellosis was initiated and subsequent whole genome sequencing identified the blood culture isolate as Brucella melitensis confirming the diagnosis of brucellosis. This case highlights the challenges in the diagnosis of brucellosis in low-incidence settings.

Background: Antimicrobial prescribing in patients approaching end of life is complex. We aimed to describe antimicrobial use in the final 4 weeks of life among hospitalized patients and identify factors associated with antimicrobial consumption. Methods: We conducted a retrospective review of antimicrobial use among inpatients during their last 4 weeks of life in a tertiary Irish hospital. Data collected included antimicrobial agents and duration of therapy, microbiological sampling, infection services input, palliative care services input, patient demographics, frailty scores, and markers of inflammation. Univariate analysis and multivariable linear regression were used to assess factors associated with antimicrobial-free time before death. Results: Two hundred and fifty-eight patients were included, with 91% receiving antimicrobials during the study period. Only 36% had a presumed infection at the time of admission. Antimicrobial use was characterized by broad-spectrum agents, did not correlate with culture results, and had a median duration (interquartile range) of 10.5 (5–18) days. Palliative care consultation (P = .004) and longer length of stay (P < .0001) were associated with a longer antimicrobial-free interval before death. Within the antimicrobial cohort, 26% developed acute kidney injury. Cessation of antimicrobial therapy often occurred late, with 40% of patients receiving antimicrobial therapy within 24 hours of death. Conclusions: There was a high burden of antimicrobial use in patients nearing the end of life, characterized by broad-spectrum, empiric therapy, often continued until hours before death. We recommend expansion of antimicrobial surveillance and collaboration between infection and palliative care services in order to optimize and rationalize antimicrobial prescribing in patients approaching end of life.

Background:Antimicrobial stewardship is essential to reducing antimicrobial resistance, reducing costs and, crucially, ensuring good patient care. Community acquired pneumonia (CAP) is a common medical condition, the symptoms of which show significant overlap with those of Covid-19. Following the Covid-19 outbreak in Ireland, patients presenting to our hospital with features of a respiratory infection were more commonly reviewed within 24-hours of admission by an infectious disease (ID) or respiratory specialist.Aims:We aimed to assess how the change in service provision with increased frequency of specialist review in CAP during the first wave of the Covid-19 pandemic affected antimicrobial stewardship and prescribing practices. Methods:Patients treated for CAP from the months of March-April 2020 were included. Retrospective data including demographics, CURB-65 score, and antimicrobial therapy were collected. Data were compared with a similar cohort treated for CAP between November 2019 and January 2020. Results:76 patients were included from the March-April 2020 cohort, with 77 from November 2019-January 2020 for comparison. An ID or respiratory specialist reviewed 35 patients from the March-April cohort within 24 hours of admission. There was a higher rate of appropriate escalation, de-escalation and continuation of antibiotics among those reviewed. Less than 20% of patients were started on antibiotics in accordance with CAP guidelines on admission, though the antibiotics initiated were frequently deemed appropriate in the clinical setting.Conclusions:Specialist review increases rates of appropriate antimicrobial prescribing and adherence with hospital guidelines in patients with CAP.